10 – 12 February 2020, Dublin, Ireland

The Probiota Series brings together experts and leaders from global industries and academia under one roof to present top-level insights and provide networking opportunities in the field of Science of the microbiome.

The 2020 event, to be held in Dublin on 10-12 February 2020, will have as guests top academics and business profiles from all over the world.

ROELMI HPC is delighted to be Gold sponsor for the event and be present playing a Round Table for IN & OUT X-BIOTICS: FROM PROBIOTIC EFFECT TO MULTIPLE APPROACHES TO REBALANCE SKIN MICROBIOME

Nowadays, the scientific community recognizes the link between localized microbiota dysbiosis and the onset of skin-related inflammatory, allergic or autoimmune diseases.

Oral probiotics are highly promising to potentially contribute not only to the management of chronic disease but also to improve patients’ quality of life, as they counteract gut dysbiosis and provide long-lasting benefits on symptoms.

However, probiotics targeting the “gut-skin-axis” are not the sole solution: different factors concur to affect microbiota homeostasis. Topical treatments are now spreading throughout probiotics-derived technologies: deactivated bacteria with prebiotic, boosting and immune-mimetic effects, post-biotic molecules rebalancing stressed microbiome, bio-balancer agents able to protect both formulations and consumer use, up to alive bacteria in dermo-cosmetics.

Where are the limits of innovation within the regulatory landscape?


Discover also our scientific poster:

A new ally to public health for preventing metabolic and cardiovascular risk: SynBalance® probiotic complex against metabolic syndrome.

Objective. This study aims to assess the ability of a probiotic formulation containing Lactobacillus Plantarum PBS067, Lactobacillus acidophilus PBS066 and Lactobacillus reuteri PBS072 to exert a positive effect on metabolic syndrome by improving body circumferences, lipid metabolic profile, chronic inflammation and also the overall quality of life. 

Conclusion. This work represents the first evidence about the efficacy of a probiotic supplement to positively modulate the metabolic syndrome markers in the elderly, known for a higher prevalence and increased CV risk. It also provides the basis for a further investigation about a preventive role of probiotics and a healthy lifestyle in reducing the onset of metabolic syndrome.